Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating
BTIG Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $29
BTIG Remains a Buy on Evolent Health (EVH)
Piper Sandler Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $18
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Evolent Health (EVH) and Palisade Bio (PALI)
J.P. Morgan Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $15
Oppenheimer Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $28
Evolent Health Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Outperform on Evolent Health, Lowers Price Target to $28
Evolent Health Analyst Ratings
Citi Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $21
RBC Capital Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $20
Evolent Health Price Target Maintained With a $20.00/Share by RBC Capital
A Quick Look at Today's Ratings for Evolent Health(EVH.US), With a Forecast Between $19 to $36
RBC Capital Sticks to Its Buy Rating for Evolent Health (EVH)
Evolent Health Is Maintained at Overweight by Barclays
Evolent Health Analyst Ratings
Truist Financial Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $24
Barclays Maintains Evolent Health(EVH.US) With Buy Rating, Cuts Target Price to $19
A Quick Look at Today's Ratings for Evolent Health(EVH.US), With a Forecast Between $27 to $63